Fenwick & West LLP represented ZymoGenetics, Inc. (NASDAQ: ZGEN), a biopharmaceutical company focused on the development and commercialization of therapeutic proteins, in a $96.6 million follow-on public offering. The Seattle-based company priced 16.1 million shares of its common stock at $6 per share.
Leerink Swann LLC acted as sole book-running manager for the offering. Wedbush Morgan Securities, Inc., William Blair & Company, LLC., Canaccord Adams Inc. and McAdams Wright Ragen, Inc. were the co-managers for the offering.
The Fenwick & West transaction team included corporate attorneys Stephen Graham, Rob Freedman, David Michaels, Gail Suniga, James Evans, Andrew Albertson and senior paralegal Ellen Welichko.
About Fenwick & West
Fenwick & West provides comprehensive legal services to technology and life sciences clients of national and international prominence. The firm has been ranked by American Lawyer Media and Global Securities as one of the top 10 IPO issuer's counsel in the United States and was recently ranked by Corporate Board Member as one of the top 5 corporate law firms in the San Francisco Bay Area for publicly traded companies.
Stephen M. Graham
Co-Chair, Life Sciences Group
Partner, Corporate Group